Difference between revisions of "Cisplatin (Platinol)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
m (Text replacement - "please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information" to "please refer to your preferred pharmacopeias or the prescribing information")
 
(98 intermediate revisions by 5 users not shown)
Line 1: Line 1:
−
Template to be used for chemotherapies:
+
==General information==
−
(strive for minimalism, focus on regimens)
+
Class/mechanism: Platinum analog, alkylating-like, producing predominantly interstrand DNA crosslinks that are cell-cycle nonspecific.<ref name="insert">[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de6302d5-85f0-4116-a709-57826c2c84fe Cisplatin (Platinol) package insert]</ref><ref>[[:File:Cisplatin.pdf | Cisplatin (Platinol) package insert (locally hosted backup)]]</ref>
 +
<br>Route: IV, intracavitary (intraperitoneal)
 +
<br>Extravasation: [[vesicant]] (concentration ≥0.5 mg/mL)/[[irritant]] (concentration less than 0.5 mg/mL)
  
−
==General information==
+
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.<ref name="insert"></ref>
−
Class: Platinum analog, alkylating-like<ref name="insert">[http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018057s080lbl.pdf Cisplatin package insert (8/2011)]</ref><ref>[http://hemonc.org/docs/chemotherapypackageinsert/cisplatin.pdf Cisplatin package insert (locally hosted backup)]</ref>
+
 
−
<br>Extravasation: [[vesicant]]
+
==Diseases for which it is established ''(work in progress)''==
 +
*[[Bladder cancer]]
 +
*[[Malignant pleural mesothelioma]]
 +
*[[Nasopharyngeal carcinoma]]
 +
*Non-Hodgkin lymphoma
 +
**[[Mantle cell lymphoma]]
 +
**[[Peripheral T-cell lymphoma]]
 +
*[[Osteosarcoma]]
 +
*[[Ovarian cancer]]
 +
*[[Testicular cancer]]
  
−
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer.  Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>.
+
==Diseases for which it is used==
 +
<div style="column-count:3;-moz-column-count:3;-webkit-column-count:3">
 +
*[[Adrenocortical carcinoma]]
 +
*[[Anal cancer]]
 +
*[[Breast cancer]]
 +
*[[Carcinoma of unknown primary]]
 +
*[[Cervical cancer]]
 +
*[[Cholangiocarcinoma]]
 +
*[[Cutaneous basal cell carcinoma]]
 +
*[[Cutaneous squamous cell carcinoma]]
 +
*[[Endometrial cancer]]
 +
*[[Esophageal cancer]]
 +
**[[Esophageal adenocarcinoma]]
 +
**[[Esophageal squamous cell carcinoma]]
 +
*[[Gallbladder cancer]]
 +
*[[Gastric cancer]]
 +
*[[Head and neck cancer]]
 +
**[[Oropharyngeal cancer, HPV-positive]]
 +
*[[Hepatoblastoma]]
 +
*[[Classical Hodgkin lymphoma]]
 +
*[[Low-grade glioma]]
 +
**[[Low-grade glioma, pediatric]]
 +
*[[Melanoma]]
 +
*[[Medulloblastoma]]
 +
*[[Multiple myeloma]]
 +
*[[Neuroblastoma]]
 +
*Non-Hodgkin lymphoma
 +
**[[Anaplastic large cell lymphoma]]
 +
**[[Diffuse large B-cell lymphoma]]
 +
**[[Extranodal NK- and T-cell lymphoma, nasal type]]
 +
**[[NK- and T-cell lymphoma]]
 +
**[[Primary mediastinal B-cell lymphoma]]
 +
**[[Transformed lymphoma]]
 +
*[[Non-small cell lung cancer]]
 +
**[[Non-small cell lung cancer, nonsquamous]]
 +
**[[Non-small cell lung cancer, squamous]]
 +
*[[Pancreatic cancer]]
 +
*[[Penile cancer]]
 +
*[[Small cell lung cancer]]
 +
*[[Soft tissue sarcoma]]
 +
*[[Thymoma]]
 +
*[[Upper tract urothelial carcinoma]]
 +
*[[Urothelial carcinoma]]
 +
*[[Vulvar cancer]]
 +
</div>
  
−
==Consent==
+
==Patient drug information==
−
*Side effects discussed for informed consent
+
*[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de6302d5-85f0-4116-a709-57826c2c84fe Cisplatin (Platinol) package insert]<ref name="insert"></ref>
 +
*[https://chemocare.com/druginfo/cisplatin.aspx Cisplatin (Platinol) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/cisplatin.aspx Cisplatin (Platinol) patient drug information (Chemocare)]</ref>
 
*[http://www.uptodate.com/contents/cisplatin-patient-drug-information Cisplatin (Platinol) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/cisplatin-patient-drug-information Cisplatin (Platinol) patient drug information (UpToDate)]</ref>
 
*[http://www.uptodate.com/contents/cisplatin-patient-drug-information Cisplatin (Platinol) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/cisplatin-patient-drug-information Cisplatin (Platinol) patient drug information (UpToDate)]</ref>
  
−
==Regimens==
+
==History of changes in FDA indication==
−
Standard format will be:
+
*1978-12-19: Initial FDA approval
−
<br><nowiki><acronym (if any)> (generic drug1, generic drug2, generic drug3, etc.) (disease)</nowiki>
+
*2010-09-02 (oldest label available at Drugs @ FDA): Indicated in established combination therapy with other approved chemotherapeutic agents in patients with metastatic [[testicular cancer|testicular tumors]] who have already received appropriate surgical and/or radiotherapeutic procedures. ''(No supporting studies are cited)''
−
<br>[http://hemonc.org/index.php?title=Special:WhatLinksHere/Cisplatin_(Platinol) List of regimens containing cisplatin]
+
*2010-09-02 (oldest label available at Drugs @ FDA): Indicated in established combination therapy with other approved chemotherapeutic agents in patients with metastatic [[ovarian cancer|ovarian tumors]] who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of PLATINOL and cyclophosphamide. ''(Based on Wiernik et al. 1992a)''
 +
*2010-09-02 (oldest label available at Drugs @ FDA): PLATINOL, as a single agent, is indicated as secondary therapy in patients with metastatic [[Ovarian cancer|ovarian tumors]] refractory to standard chemotherapy who have not previously received PLATINOL therapy. ''(Based on Wiernik et al. 1992a)''
 +
*2010-09-02 (oldest label available at Drugs @ FDA): Indicated as a single agent for patients with transitional cell [[bladder cancer]] which is no longer amenable to local treatments, such as surgery and/or radiotherapy. ''(No supporting studies are cited)''
 +
 
 +
==History of changes in EMA indication==
 +
*1978-12-19: EURD
 +
==History of changes in PMDA indication==
 +
*2012-02-22: New additional indication and a new dosage for the treatment of [[:Category:Biliary tract cancers|biliary tract cancer]].
 +
 
 +
==Also known as==
 +
*'''Code name:''' NSC-119875
 +
*'''Generic names:''' CDDP, cis-diamminedichloroplatinum III, cis-platinum, cisplatinum, DACP, DDP
 +
*'''Brand names:'''
 +
{| class="wikitable" style="text-align:center;"
 +
!colspan="8" align="center" style="background-color:#0066FF"| '''Synonyms'''
 +
|-
 +
|Abiplatin
 +
|Axiplat
 +
|Biocisplatinum
 +
|Bioplatino
 +
|Blastolem
 +
|Briplatin
 +
|Brisplatin
 +
|C-Platin
 +
|-
 +
|Ceplatin
 +
|Ciplatan
 +
|Ciplexal
 +
|Cis-GRY
 +
|Cismaplat
 +
|Cispatin
 +
|Cisplamerck
 +
|Cisplan
 +
|-
 +
|Cisplasol
 +
|Cisplatex
 +
|Cisplatine
 +
|Cisplatino
 +
|Cisplatyl
 +
|Cisteen
 +
|Citoplatino
 +
|Citosin
 +
|-
 +
|Cysplatyna
 +
|Cytoplatin
 +
|Docistin
 +
|Elvecis
 +
|Fauldcispla
 +
|Ifapla
 +
|Kemoplat
 +
|Lederplatin
 +
|-
 +
|Metaplatin
 +
|Neoplat
 +
|Neoplatin
 +
|Noveldexis
 +
|Oncoplatin AQ
 +
|Peyrone's Chloride
 +
|Peyrone's Salt
 +
|Placis
 +
|-
 +
|Plastistil
 +
|Platamin
 +
|Platamine
 +
|Platiblastin
 +
|Platicis
 +
|Platidiam
 +
|Platikem
 +
|Platil
 +
|-
 +
|Platimit
 +
|Platin
 +
|Platinex
 +
|Platinil
 +
|Platino II Filaxis
 +
|Platinol
 +
|Platinox
 +
|Platinoxan
 +
|-
 +
|Platiran
 +
|Platistil
 +
|Platistin
 +
|Platistine
 +
|Platosin
 +
|Randa
 +
|Romcis
 +
|Sicatem
 +
|-
 +
|Sinplatin
 +
|Sisplanil
 +
|Tecnoplatin
 +
|Tisplal
 +
|Unistin
 +
|}
  
 
==References==
 
==References==
 
<references/>
 
<references/>
 +
 +
[[Category:Drugs]]
 +
[[Category:Intravenous medications]]
 +
[[Category:Intracavitary medications]]
 +
[[Category:Vesicant]]
 +
[[Category:Irritant]]
 +
 +
[[Category:Platinum agents]]
 +
[[Category:Alkylating agents]]
 +
 +
[[Category:Carcinoma of unknown primary medications]]
 +
[[Category:Adrenocortical carcinoma medications]]
 +
[[Category:Anal cancer medications]]
 +
[[Category:Anaplastic large cell lymphoma medications]]
 +
[[Category:Cutaneous basal cell carcinoma medications]]
 +
[[Category:Bladder cancer medications]]
 +
[[Category:Breast cancer medications]]
 +
[[Category:Cervical cancer medications]]
 +
[[Category:Cholangiocarcinoma medications]]
 +
[[Category:Cutaneous squamous cell carcinoma medications]]
 +
[[Category:Diffuse large B-cell lymphoma medications]]
 +
[[Category:Endometrial cancer medications]]
 +
[[Category:Esophageal adenocarcinoma medications]]
 +
[[Category:Esophageal cancer medications]]
 +
[[Category:Esophageal squamous cell carcinoma medications]]
 +
[[Category:Extranodal NK- and T-cell lymphoma, nasal type medications]]
 +
[[Category:Gallbladder cancer medications]]
 +
[[Category:Gastric cancer medications]]
 +
[[Category:Head and neck cancer medications]]
 +
[[Category:Hepatoblastoma medications]]
 +
[[Category:Classical Hodgkin lymphoma medications]]
 +
[[Category:Low-grade glioma medications]]
 +
[[Category:Low-grade glioma, pediatric medications]]
 +
[[Category:Mantle cell lymphoma medications]]
 +
[[Category:Medulloblastoma medications]]
 +
[[Category:Melanoma medications]]
 +
[[Category:Malignant pleural mesothelioma medications]]
 +
[[Category:Multiple myeloma medications]]
 +
[[Category:Nasopharyngeal carcinoma medications]]
 +
[[Category:Neuroblastoma medications]]
 +
[[Category:Neuroendocrine carcinoma medications]]
 +
[[Category:NK- and T-cell lymphoma medications]]
 +
[[Category:Non-small cell lung cancer medications]]
 +
[[Category:Non-small cell lung cancer, nonsquamous medications]]
 +
[[Category:Non-small cell lung cancer, squamous medications]]
 +
[[Category:Oropharyngeal cancer medications]]
 +
[[Category:Osteosarcoma medications]]
 +
[[Category:Ovarian cancer medications]]
 +
[[Category:Pancreatic cancer medications]]
 +
[[Category:Penile cancer medications]]
 +
[[Category:Peripheral T-cell lymphoma medications]]
 +
[[Category:Primary mediastinal B-cell lymphoma medications]]
 +
[[Category:Small cell lung cancer medications]]
 +
[[Category:Soft tissue sarcoma medications]]
 +
[[Category:Testicular cancer medications]]
 +
[[Category:Thymoma medications]]
 +
[[Category:Transformed lymphoma medications]]
 +
[[Category:Upper tract urothelial carcinoma medications]]
 +
[[Category:Urothelial carcinoma medications]]
 +
[[Category:Vulvar cancer medications]]
 +
 +
[[Category:FDA approved in 1978]]
 +
[[Category:EMA approved in 1978]]
 +
[[Category:WHO Essential Cancer Medicine]]

Latest revision as of 01:04, 29 June 2024

General information

Class/mechanism: Platinum analog, alkylating-like, producing predominantly interstrand DNA crosslinks that are cell-cycle nonspecific.[1][2]
Route: IV, intracavitary (intraperitoneal)
Extravasation: vesicant (concentration ≥0.5 mg/mL)/irritant (concentration less than 0.5 mg/mL)

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.[1]

Diseases for which it is established (work in progress)

Diseases for which it is used

Patient drug information

History of changes in FDA indication

  • 1978-12-19: Initial FDA approval
  • 2010-09-02 (oldest label available at Drugs @ FDA): Indicated in established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. (No supporting studies are cited)
  • 2010-09-02 (oldest label available at Drugs @ FDA): Indicated in established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of PLATINOL and cyclophosphamide. (Based on Wiernik et al. 1992a)
  • 2010-09-02 (oldest label available at Drugs @ FDA): PLATINOL, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received PLATINOL therapy. (Based on Wiernik et al. 1992a)
  • 2010-09-02 (oldest label available at Drugs @ FDA): Indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy. (No supporting studies are cited)

History of changes in EMA indication

  • 1978-12-19: EURD

History of changes in PMDA indication

Also known as

  • Code name: NSC-119875
  • Generic names: CDDP, cis-diamminedichloroplatinum III, cis-platinum, cisplatinum, DACP, DDP
  • Brand names:
Synonyms
Abiplatin Axiplat Biocisplatinum Bioplatino Blastolem Briplatin Brisplatin C-Platin
Ceplatin Ciplatan Ciplexal Cis-GRY Cismaplat Cispatin Cisplamerck Cisplan
Cisplasol Cisplatex Cisplatine Cisplatino Cisplatyl Cisteen Citoplatino Citosin
Cysplatyna Cytoplatin Docistin Elvecis Fauldcispla Ifapla Kemoplat Lederplatin
Metaplatin Neoplat Neoplatin Noveldexis Oncoplatin AQ Peyrone's Chloride Peyrone's Salt Placis
Plastistil Platamin Platamine Platiblastin Platicis Platidiam Platikem Platil
Platimit Platin Platinex Platinil Platino II Filaxis Platinol Platinox Platinoxan
Platiran Platistil Platistin Platistine Platosin Randa Romcis Sicatem
Sinplatin Sisplanil Tecnoplatin Tisplal Unistin

References

  1. ↑ 1.0 1.1 1.2 Cisplatin (Platinol) package insert
  2. ↑ Cisplatin (Platinol) package insert (locally hosted backup)
  3. ↑ Cisplatin (Platinol) patient drug information (Chemocare)
  4. ↑ Cisplatin (Platinol) patient drug information (UpToDate)
Retrieved from "https://hemonc.org/w/index.php?title=Cisplatin_(Platinol)&oldid=87344"